Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 25 studies | 30% ± 13% | |
smooth muscle cell | 23 studies | 32% ± 12% | |
fibroblast | 18 studies | 29% ± 9% | |
glutamatergic neuron | 10 studies | 45% ± 26% | |
astrocyte | 10 studies | 31% ± 13% | |
GABAergic neuron | 8 studies | 44% ± 23% | |
myofibroblast cell | 8 studies | 24% ± 8% | |
endothelial cell | 8 studies | 32% ± 10% | |
oligodendrocyte | 7 studies | 31% ± 14% | |
interneuron | 6 studies | 47% ± 20% | |
platelet | 6 studies | 24% ± 8% | |
adipocyte | 6 studies | 33% ± 12% | |
oligodendrocyte precursor cell | 6 studies | 28% ± 9% | |
connective tissue cell | 4 studies | 24% ± 9% | |
cardiac muscle cell | 4 studies | 23% ± 5% | |
Mueller cell | 4 studies | 31% ± 11% | |
amacrine cell | 4 studies | 45% ± 16% | |
retina horizontal cell | 4 studies | 39% ± 16% | |
retinal cone cell | 4 studies | 51% ± 19% | |
retinal rod cell | 4 studies | 39% ± 9% | |
muscle cell | 4 studies | 43% ± 25% | |
microglial cell | 3 studies | 33% ± 23% | |
GABAergic amacrine cell | 3 studies | 39% ± 16% | |
glycinergic amacrine cell | 3 studies | 44% ± 15% | |
mast cell | 3 studies | 19% ± 2% | |
megakaryocyte | 3 studies | 37% ± 9% | |
type II pneumocyte | 3 studies | 19% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 99% | 7223.03 | 242 / 245 | 95% | 22.46 | 475 / 502 |
thymus | 98% | 3122.68 | 641 / 653 | 92% | 78.17 | 556 / 605 |
intestine | 98% | 6957.73 | 948 / 966 | 79% | 7.21 | 418 / 527 |
lung | 99% | 4174.48 | 570 / 578 | 76% | 6.83 | 874 / 1155 |
breast | 94% | 2856.34 | 432 / 459 | 78% | 10.65 | 875 / 1118 |
esophagus | 80% | 8407.25 | 1155 / 1445 | 83% | 12.55 | 151 / 183 |
pancreas | 70% | 1166.63 | 228 / 328 | 90% | 9.83 | 161 / 178 |
bladder | 95% | 3470.24 | 20 / 21 | 54% | 5.08 | 271 / 504 |
uterus | 92% | 2593.29 | 156 / 170 | 54% | 5.90 | 248 / 459 |
stomach | 52% | 2155.95 | 188 / 359 | 79% | 8.90 | 227 / 286 |
adrenal gland | 55% | 991.42 | 143 / 258 | 52% | 4.11 | 119 / 230 |
kidney | 27% | 508.40 | 24 / 89 | 78% | 8.60 | 704 / 901 |
blood vessel | 100% | 13048.48 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 91% | 3401.97 | 1090 / 1204 | 0% | 0 | 0 / 0 |
skin | 38% | 690.09 | 685 / 1809 | 31% | 1.84 | 148 / 472 |
tonsil | 0% | 0 | 0 / 0 | 58% | 3.29 | 26 / 45 |
ovary | 39% | 871.28 | 71 / 180 | 16% | 0.94 | 69 / 430 |
brain | 2% | 43.94 | 66 / 2642 | 42% | 2.10 | 293 / 705 |
heart | 38% | 730.76 | 331 / 861 | 0% | 0 | 0 / 0 |
muscle | 38% | 691.92 | 303 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 30% | 1.97 | 24 / 80 |
liver | 0% | 0 | 0 / 226 | 14% | 1.52 | 57 / 406 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.45 | 3 / 29 |
spleen | 6% | 86.63 | 14 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 3.54 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0060282 | Biological process | positive regulation of oocyte development |
GO_0010749 | Biological process | regulation of nitric oxide mediated signal transduction |
GO_0048599 | Biological process | oocyte development |
GO_0019933 | Biological process | cAMP-mediated signaling |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0055118 | Biological process | negative regulation of cardiac muscle contraction |
GO_0055119 | Biological process | relaxation of cardiac muscle |
GO_0042098 | Biological process | T cell proliferation |
GO_0046069 | Biological process | cGMP catabolic process |
GO_0010613 | Biological process | positive regulation of cardiac muscle hypertrophy |
GO_0005575 | Cellular component | cellular_component |
GO_0005829 | Cellular component | cytosol |
GO_0004114 | Molecular function | 3',5'-cyclic-nucleotide phosphodiesterase activity |
GO_0004115 | Molecular function | 3',5'-cyclic-AMP phosphodiesterase activity |
GO_0047555 | Molecular function | 3',5'-cyclic-GMP phosphodiesterase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0030553 | Molecular function | cGMP binding |
Gene name | PDE5A |
Protein name | cGMP-specific phosphodiesterase PDE5A1 cGMP-specific phosphodiesterase PDE5A2 Uncharacterized protein PDE5A Phosphodiesterase 5A cGMP-specific 3',5'-cyclic phosphodiesterase (EC 3.1.4.35) (cGMP-binding cGMP-specific phosphodiesterase) (CGB-PDE) cGMP-specific phosphodiesterase PDE5A1 (cGMP-specific phosphodiesterase type 5A) Phosphodiesterase (EC 3.1.4.-) |
Synonyms | hCG_38154 PDE5 |
Description | FUNCTION: Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP . Specifically regulates nitric-oxide-generated cGMP . . |
Accessions | ENST00000264805.9 [O76074-2] O76074 ENST00000354960.8 [O76074-1] Q9P0K3 H0YA14 C9JGT3 Q9P0K6 Q9P0K5 ENST00000394439.5 Q4W5L4 ENST00000420633.1 G5E9C5 ENST00000503412.1 Q9P0K4 |